The Never-ending fight against cancer is in full-force and the results have been on the brighter side of things. Some of the most advanced cancer-fighting medications are upon humanity, and they’re creating dramatic results by saving lives at a higher rate. Dr. Clay Siegall, CEO of Seattle Genetics, is one of the most loved figures in this dynamic field of work. He has a long history of working in the medical industry, and he has worked with many high profile names. This includes the National Institute of Health, the National Cancer Institute and Bristol Myers Squibb. The guy has served on the Boards of Directors for Alder BioPharmaceuticals and Ultragenyx.
The success of Seattle Genetics comes from multiple avenues, whether it’s great leadership, strategic marketing or from licensing. Thanks to his great business sense, Siegall has been able to strike-up multiple strategic license deals with some of the industry’s most prominent names. This includes:
With this licensing, the company can distribute the advanced medications to other areas around the globe. This means that 65 different countries around the globe can now use Seattle Genetics’ ADCETRIS drug. ADCETRIS is an antibody drug conjugate, and it is far superior to any other cancer fighting drug of today. It has helped the company bring in over $350 million in which it has helped the company’s stock triple in a span of five years. That’s right! Seattle Genetics is outperforming everyone else at a consistent rate. The 21st century is Seattle Genetics’ playground as the company has 20 more advanced drugs in its pipeline of success.
The great thing about all of this news is that Dr. Clay Siegall is in control of it all. This well-accomplished doctor is setting new trends, and he is changing the status quo.